Page 74 - GALENIKA MEDICAL JOURNAL

16. Bantle JP, Boudreau RJ, Ferris TF. Suppression of plasma renin activity by 32. Rüster C, Wolf G. Renin-angiotensin-aldosterone system and
cyclosporine. Am J Med. 1987 Jul;83(1):59-64. progression of renal disease. J Am Soc Nephrol. 2006 Nov;17(11):2985-
91.
17. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-
associated chronic nephropathy. N Engl J Med. 1984 Sep 13;311(11):699- 33. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, et
705. al. ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors
in renal transplantation. N Engl J Med. 2007 Dec 20;357(25):2562-75.
18. Lewis RM, Janney RP, Van Buren CT, Kerman RH, Herson J, Kerr NA, et al.
A retrospective analysis of long-term renal allograft function associated 34. Ekberg H, Grinyó J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A,
with cyclosporine-prednisone immunosuppressive therapy. Transplant et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab
Proc. 1988 Jun;20(3 Suppl 3):534-9. and corticosteroids in renal allograft recipients: the CAESAR Study. Am J
Transplant. 2007 Mar;7(3):560-70.
19. M. Colombo, R. Perego and G. Bellia, "Cyclosporine-Associated
Nephrotoxicity," Open Journal of Nephrology, Vol. 3 No. 3, 2013, pp. 35. Matas AJ. Chronic progressive calcineurin nephrotoxicity: an overstated
168-180. concept. Am J Transplant. 2011 Apr;11(4):687-92.
20. Moyer TP, Post GR, Sterioff S, Anderson CF. Cyclosporine nephrotoxicity 36. Burke JF Jr, Pirsch JD, Ramos EL, Salomon DR, Stablein DM, Van Buren
is minimized by adjusting dosage on the basis of drug concentration in DH, et al. Long-term efficacy and safety of cyclosporine in renal-
blood. Mayo Clin Proc. 1988 Mar;63(3):241-7. transplant recipients. N Engl J Med. 1994 Aug 11;331(6):358-63.
21. Holt DW, Marsden JT, Johnston A, Bewick M, Taube DH. Blood 37. Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, et al.
cyclosporin concentrations and renal allograft dysfunction. Br Med J Evidence for antibody-mediated injury as a major determinant of late
(Clin Res Ed). 1986 Oct 25;293(6554):1057-9. kidney allograft failure. Transplantation. 2010 Jul 15;90(1):68-74.
22. Flores C, Fouquet G, Moura IC, Maciel TT, Hermine O. Lessons to Learn 38. Shah SR, Altaf A, Arshad MH, Mari A, Noorani S, Saeed E, et al. Use of
From Low-Dose Cyclosporin-A: A New Approach for Unexpected Clinical Cyclosporine Therapy in Steroid Resistant Nephrotic Syndrome (SRNS):
Applications. Front Immunol. 2019 Mar 28;10:588. A Review. Glob J Health Sci. 2015 Aug 6;8(4):136-41.
23. Kahan BD. Cyclosporine. N Engl J Med. 1989 Dec 21;321(25):1725-38. 39. Moroni G, Doria A, Ponticelli C. Cyclosporine (CsA) in lupus nephritis:
assessing the evidence. Nephrol Dial Transplant. 2009 Jan;24(1):15-20.
24. Kahan BD, Keown P, Levy GA, Johnston A. Therapeutic drug monitoring
of immunosuppressant drugs in clinical practice. Clin Ther. 2002 40. Ponticelli C, Podestà MA. Calcineurin inhibitors in lupus nephritis. J
Mar;24(3):330-50; discussion 329. Nephrol. 2021 Apr;34(2):399-402.
25. Calne RY, Rolles K, White DJ, Thiru S, Evans DB, McMaster P, et al. 41. Weissman S, Chris-Olaiya A, Mehta TI, Aziz M, Alshati A, Berry R, et al. A
Cyclosporin A initially as the only immunosuppressant in 34 recipients novel player: cyclosporine therapy in the management of inflammatory
of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet. bowel disease. Transl Gastroenterol Hepatol. 2019 Sep 10;4:67.
1979 Nov 17;2(8151):1033-6.
42. Rosmarin DM, Lebwohl M, Elewski BE, Gottlieb AB. National Psoriasis
26. Murray BM, Paller MS, Ferris TF. Effect of cyclosporine administration Foundation. Cyclosporine and psoriasis: 2008 National Psoriasis
on renal hemodynamics in conscious rats. Kidney Int. 1985 Foundation Consensus Conference. J Am Acad Dermatol. 2010
Nov;28(5):767-74. May;62(5):838-53.
27. Hortelano S, Castilla M, Torres AM, Tejedor A, Boscá L. Potentiation
by nitric oxide of cyclosporin A and FK506-induced apoptosis in renal
proximal tubule cells. J Am Soc Nephrol. 2000 Dec;11(12):2315-23.
28. Höcherl K, Dreher F, Vitzthum H, Köhler J, Kurtz A. Cyclosporine A
suppresses cyclooxygenase-2 expression in the rat kidney. J Am Soc Konflikt interesa: Nema
Nephrol. 2002 Oct;13(10):2427-36.
Primljeno: 16. 10. 2023.
29. Myers BD, Sibley R, Newton L, Tomlanovich SJ, Boshkos C, Stinson E,
Luetscher JA, Whitney DJ, Krasny D, Coplon NS, et al. The long-term Prihvaćeno: 06. 11. 2023.
course of cyclosporine-associated chronic nephropathy. Kidney Int. Onlajn: 01. 12. 2023.
1988 Feb;33(2):590-600.
30. Isnard Bagnis C, Tezenas du Montcel S, Beaufils H, Jouanneau C, Jaudon
MC, Maksud P, et al. Long-term renal effects of low-dose cyclosporine
in uveitis-treated patients: follow-up study. J Am Soc Nephrol. 2002
Dec;13(12):2962-8.
31. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity.
Clin J Am Soc Nephrol. 2009 Feb;4(2):481-508.

72 DOI: 10.5937/Galmed2308067N